anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a hypotensive agent exhibiting excellent hypotensive actions and to provide a method for producing the same and to obtain a propolis composition and a food formulation.  &lt;P&gt;SOLUTION: The hypotensive agent and the food formulation comprise at least one kind selected from compounds represented by formula (1) (wherein, X is hydrogen, an alkoxyl group, hydroxy group, a caffeoyloxy group or a p-coumaroxy group, with the proviso that the carbon number of the alkoxyl group is 1-3). The method for producing the hypotensive agent comprises an extraction step, a separation step and a collection step. In the extraction step, polyphenols are extracted from a polyphenol-containing material and the resultant component is separated in the separation step. In the collection step, at least the one kind selected from the compounds represented by formula (1) is collected using fluorescence from excitation light in an ultraviolet region as an index. The propolis composition comprises at least the one kind selected from the compounds in addition to a propolis extract.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
FIELD: biology, medicine. ^ SUBSTANCE: invention relates to chemical compounds and compositions that can be used as modulating agents of phototoxicity of skin cells. Proposed &#34;modulators&#34; relate to material that can either accelerate or decelerate damage of cells, for example, skin cells caused by effect (exposition) of light, for example, UV-rays of type A. Modulators are chosen from group consisting of 3-hydroxyproline pharmacophor or proline, 4-hydroxyproline or its alkyl ester. Invention provides modulating effect of phototoxicity of cells wherein modulators relate to molecule that can be molecule of skin components, in particular, collagen. ^ EFFECT: improved and enhanced method of modulation. ^ 14 cl, 2 tbl, 13 dwg, 10 ex
FIELD: medicine, gastroenterology. SUBSTANCE: invention relates to treatment of patients with chronic gastritis at secretory insufficiency. Method involves administration of beralk and mineral water &#34;Mirninskaya&#34; at the definite regime and at the course treatment for 21 days. Method results to the normalization of acid-producing function of stomach mucosa, motor-evacuatory function of gastroenteric tract, decrease of inflammatory process at the total improvement of gastroduodenal mucosa tissue trophism. EFFECT: improved method of treatment. 3 tbl, 2 ex
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medical examination support system capable of facilitating acquisition of an operation history, and a program therefor.  &lt;P&gt;SOLUTION: The medical examination support system 1 comprises a control part 11, a storage part 12, an identification information assignment part 13, and a display part 15. The storage part 12 stores operation information of each operation performed to a patient. The identification information assignment part 13 assigns specific operation identification information to operation information of a preliminarily designated kind of operation (laser operation). The control part 11 displays a list in which operation information with the specific operation identification information assigned thereto is arranged in the order of time series on an operation history display part 2200 of an operation history display screen 2000, and displays a list in which operation information with no specific operation identification information assigned thereto is arranged in the order of time series on an operation history display part 2100.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
1,143,996. Vaccine for virus infections in dogs. RHONE - POULENC S.A. 17 Nov., 1966 [17 Nov., 1965], No. 51610/66. Heading A5B [Also in Division C6] A vaccine comprises an inactivated virus suspension which is prepared by inoculating a canine cell culture with a virus isolated by cultivation in vetro, from the renal cells of a dog with bronchopneumonia and rhinitis, incubating the cell culture until a cytopathogenic effect is produced, liberating the virus from the cells and removing cell debris, and then inactivating the virus to give the required suspension. The virus is one giving rise to lesions of pneumonia, encephalitis, hepatitis and nephritis in young dogs. The infected renal cells are preferably obtained from a pup, and the canine cell culture may be either an epithelial cell culture from a healthy dog&#39;s kidneys, or preferably a fibroblastic cell culture from the lungs of a dog foetus. Conventional culture media are used, with added streptomycin, penicillin and nystatin to prevent extraneous infection, and the virus liberated by freezing and thawing the cells to burst them. The virus may be inactivated by incubating at 37‹C., with # - propiolactone or by ultra-violet irradiation. The suspension may be used directly as a vaccine, or preferably admixed with an adjuvant such as a mineral or vegetable oil with an emulsifier, or aluminium hydroxide, and may be administered to dogs by intra-muscular injection, to afford protection against infection by the virus.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for producing a fish-derived antibody, and a method for measuring the strength of the fish-derived antibody.  &lt;P&gt;SOLUTION: This method for producing the fish-derived antibody is provided by orally administering E. coli or a yeast expressing an antigen to the fishes. The method for producing the fish-derived antibody is provided with that the fishes are zebrafishes. The method for producing the fish-derived antibody is provided with that the antigen is GFP or 380R. The fish-derived antibody obtained by the above methods is provided. The fish-derived antibody is an IgM. The method for measuring the strength of the fish-derived antibody by comparing it with the strength of an antibody to be an index is provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
Automated assistance program qualification and enrollment are provided. An assistance program qualification and enrollment (APQE) system determines whether a user qualifies for an assistance program that offers assistance with an ongoing transaction record with a service provider. The APQE system generates a set of questions based on qualification data (used to make a qualification determination) that are not included in collected user data and financial data about the user. The user&#39;s qualification is based on an evaluation of the user data, financial data, and user-provided responses to the questions. If the user qualifies for the assistance program, an option is provided to the user to enroll in the assistance program. If additional information is needed to complete an enrollment process for the assistance program, an interface is provided that enables the user to provide the data for completing the process.
PURPOSE:To obtain the titled alloy which can be melted in a conventional equipment and has high bonding strength to an adhesive resin by adding specified amounts of Cu, Co, In and Cr to Ni. CONSTITUTION:This alloy consists of, by weight, 3-30% Cu, 3-25% Co, 0.5- 25% In, 1-20% Cr and the balance Ni. The alloy has &lt;=1,100 deg.C m.p. and can be melted with the heat source of a conventional equipment. The alloy has high bonding strength to an adhesive resin contg. 4-META or the like, and it also passes percolation test.
PURPOSE:To extract the medicinal substance completely from the leaves of Sasa albo-marginata, by drying and cutting the raw leaves of the vegetable into fine pieces, immersing in water, boiling the water to concentrate the water-soluble substances, adding another concentrated liquid prepared in the similar manner as above, boiling the mixture at a specific temperature, separating the supernatant liquid from the product, and boiling and concentrating the liquid. CONSTITUTION:Raw leaves of Sasa albo-marginata are dried and cut to fine pieces. The cut leaves are immersed in water in a pan to effect the dissolution of the water- soluble substances, and the solution is concentrated to a proper extent by boiling to obtain the first concentrated liquid. Another concentrated liquid is prepared in a similar manner as the above process, and is mixed with a small amount of the first concentrated liquid. The mixture is heated for 6-12hr until the temperature reaches 120- 160 deg.C, mixed with warm water, and boiled. The supernatant liquid is separated from the product, concentrated by boiling, and cooled to precipitate the objective medicinal component. The precipitate has a molecular weight of &gt;=10,000, and 30% of which is determined mainly as the polysaccharide of formula (galacturonic acid). The medicinal component containing said saccharide can be extracted more completely by this process.
A substance containing sulphur in a chemically active condition is made by mixing bentonite with selenium sulphide, for example in equal parts, heating, for example, to a temperature of approximately 125-150 DEG  C., until the selenium sulphide is fused, cooling the mass and converting it to a powder.  For use the powder may be suspended in water to a consistency varying from a paste to a colloidal suspension.  Specification 351,188 is referred to.  The Specification as open to inspection under Sect. 91 (3) (a) comprises also the use of any combination of selenium and sulphur and hydrophilic substances such as fuller&#39;s earth and silica gel. This subject-matter does not appear in the Specification as accepted.ALSO:A substance containing sulphur in a chemically active condition is made by mixing bentonite with selenium sulphide, for example in equal parts, heating, for example to a temperature of approximately 125 DEG  to 150 DEG  C., until the selenium sulphide is fused, cooling the mass and converting it to a powder.  The product may be used, with or without accelerators, as a vulcanizing agent for rubber.  Specification 351,188 is referred to.  The Specification as open to inspection under Sect. 91 (3) (a) comprises also the use of any combination of selenium and sulphur and hydrophilic substances such as fuller&#39;s earth and silica gel. This subject-matter does not appear in the Specification as accepted.ALSO:A substance containing sulphur in a chemically active condition is made by mixing bentonite with selenium sulphide, for example in equal parts, heating for example to a temperature of approximately 125-150 DEG  C., until the selenium sulphide is fused, cooling the mass and converting it to a powder.  For use the powder may be suspended in water to a consistency varying from a paste to a colloidal suspension.  The paste may be used as a therapeutic agent in the treatment of skin diseases such as eczema, or as a skin cream for protection against, for example, mercury.  Aqueous dispersions may be used as fungicides and the substance may also be used, with or without accelerators, as a p  vulcanizing agent for rubber.  Specification 351,188 is referred to.  The Specification as open to inspection under Sect. 91 (3) (a) comprises also the use of say combination of selenium and sulphur and hydrophilic substances such as fuller&#39;s earth and silica gel. This subject-matter does not appear in the Specification as accepted.
The present invention provides a cobalamin-drug conjugate suitable for the treatment of tumor related diseases. Cobalamin is indirectly covalently bound to an antitumor drug via a cleavable linker and one or more optional spacers. Cobalanin is covalently bound to a first spacer or the cleavable linker via the 5&#39;-OH of the cobalamin ribose ring. The drug is bound to a second spacer of the cleavable linker via an existing or added functional group on the drug. After administration, the conjugate forms a complex with transcobalamin (any of its isoforms). The complex then binds to a receptor on a cell membrane and is taken up into the cell. Once in the cell, an intracellular enzyme cleaves the conjugate thereby releasing the drug. Depending upon the structure of the conjugate, a particular class or type of intracellular enzyme affects the cleavage. Due to the high demand for cobalamin in growing cells, tumor cells typically take up a higher percentage of the conjugate than do normal non-growing cells. The conjugate of the invention advantageously provides a reduced systemic toxicity and enhanced efficacy as compared to a corresponding free drug.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a cosmetic and a skin preparation for external use blended with a poly-γ-L-glutamic acid and/or its salt and an antiaging agent, without having stickiness and excellent in refreshing feeling.  &lt;P&gt;SOLUTION: This cosmetic composition without having the stickiness and excellent in the refreshing feeling contains the poly-γ-L-glutamic acid and/or its salt and the antiaging agent, while maintaining the effect of the antiaging agent. The antiaging agent may be an anti-inflammatory agent and/or an antioxidant. Further, the cosmetic composition may contain a humectant, an ultraviolet light absorbent and/or an anti-bacterial agent. The cosmetic composition can be utilized as a cosmetic, quasi-drug, medical supply or medicine.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
1,174,366. Ferrites. YEDA RESEARCH &amp; DEVELOPMENT CO. Ltd. 11 April, 1968 [18 April, 1967], No. 17500/68. Heading A5B. [Also in Division C1] Diagnostic and/or therapeutic compositions comprise a contrast medium containing a magnetic ferrite having a particle size of no more than 50 microns and exhibiting a saturation magnetization of from 27 to 80 e.m.u. per gram. The ferrite may be Mg, Mg-Zn, Ba, Mn, Mn-Zn or Ni ferrite, magnetite or ferromagnetic garnets. The contrast medium may contain magnesium ferrite, 8-ferric oxide and a guar gum stabilizer. The composition may be administered orally in the form of an aqueous slurry and the patient is then subjected to an externally applied magnetic field to concentrate the composition in the particular organ or cavity to be diagnosed or treated. The composition may also contain barium sulphate and, for ulcer therapy, magnesium hydroxide or oxide.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a medicine to quickly and continuously relieve pathological conditions of a patient suffering from disorders relating to gastric acid secretion; and to provide a therapeutic method whereby pathological conditions of the patient suffering from the disorders relating to gastric acid secretion are quickly and continuously relieved.  &lt;P&gt;SOLUTION: The oral pharmaceutical dosage form includes pharmacologically effective amounts of an acid-sensitive proton pump inhibitor and H2 receptor antagonist, together with at least one pharmaceutically acceptable excipient which brings delayed and/or extended release of the inhibitor. The H2 receptor antagonist is contained in the dosage form in a quickly releasable form after administration. The dosage form is suitable for treatment of disorders caused by excessive gastric acid secretion, providing a proper combination of quick appearance of the effects and long duration time thereof. The invention also relates to the production method of the dosage form and the therapeutic method for relieving pathological conditions relating to gastric acid secretion.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a film preparation for oral cavity application, having moderate strength with a simple composition, producible by a simple procedure, easily soluble in the oral cavity and miscible with food materials, or the like, at high mixing ratios.  &lt;P&gt;SOLUTION: This film preparation for oral cavity application is produced by compounding pregelatinized starch and/or pullulan, an enzymatically modified starch and a plasticizer. Usable examples of the pregelatinized starch are pregelatinized potato starch, pregelatinized tapioca starch and pregelatinized corn starch, and the enzymatically modified starch is the decomposition product of a hydroxyalkylated starch with an enzyme and the plasticizer is a polyhydric alcohol, a sugar alcohol or vegetable oil-and-fat. The film preparation for oral cavity application can further be compounded with a food material at a high compounding ratio, i.e. 40 mass% based on the total film preparation.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PROBLEM TO BE SOLVED: To obtain the subject pharmaceutical preparation useful as a therapeutic agent or a preventing agent for glucose tolerance disorders, diabetes, hyperlipemia, etc., by including a specific indole derivative or its salt as an active ingredient therein. SOLUTION: This pharmaceutical preparation comprises a compound represented by formula I [R&lt;1&gt; is H, a halogen, nitro a (protected)carboxy, an acyl, etc.; R&lt;2&gt; is a halogen, a lower alkenyl, an acyl, a (protected)carboxy, etc.; R&lt;3&gt; is a lower alkenyl or a lower alkyl; R&lt;4&gt; is a (protected)carboxy, an acyl, cyano, a halogen, etc.], e.g. methyl 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6- carboxylate or its pharmaceutically permissible salt as an active ingredient. The compound represented by formula I is preferably obtained by reacting, e.g. a compound represented by formula II or its salt with a compound represented by formula III or its salt in the presence of an inorganic base or an organic base in an organic solvent.
Nicotinic acid N-oxide is prepared by heating with stirring nicotinic acid, acetic acid and perhydrol until no further gas is evolved.  Its salts, e.g. the sodium and magnesium salts, may be prepared by salification with the corresponding base.ALSO:Pharmaceutical compositions having blood cholesterol lowering activity comprise a carrier and nicotinic acid N-oxide having the formula &lt;FORM:0951732/A5-A6/1&gt; or a pharmaceutically acceptable salt thereof, e.g. the sodium or magnesium salt.  They may be in conventional forms suitable for oral, parenteral and rectal administration, e.g. a tablet, pill, powder, capsule, injectable solution or suppository.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical composition having excellent nephritis remedying action and/or endotoxin shock protecting action. SOLUTION: This composition contains an indane derivative of formula (R&lt;1&gt; is a lower alkyl, a lower alkenyl, etc.; R&lt;2&gt; is H or a lower alkyl; X is carbonyl or thiocarbonyl; Alk is single bond or a lower alkylene; the dotted line represents the presence or absence of a double bond) or its salt as an active component. It can be administered by oral or parenteral administration at a dose of 1-300mg/kg, preferably 3-100mg/kg for oral administration and 0.01-50mg/kg, preferably 0.1-20mg/kg for parenteral administration. The agent is effective for the prevention and treatment of nephritis such as glomerular nephritis, immunoglobulin A nephropathy, nephrotic syndrome, lupus erythematosus nephritis, etc., and the prevention and treatment of endotoxin shock in a patient of grave infection with Gram-negative bacteria.  It has little side action on circulatory system such as the influence on pulse rate and blood pressure.
In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5&#39;-CTAGGGCGGGCGGGACTCACCTAC-3&#39; or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the region from V beta  to J beta  of the V beta 13.1 gene in V beta 13.1 T cells, wherein the sequences of the oligonucleotide and the nucleic acid are not found on the same strand of the V beta 13.1 gene pair, to amplify a portion of the V beta 13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting a LGRAGLTY motif found in T cell receptors of V beta 13.1 T cells. This motif is associated with autoimmune diseases, such as multiple sclerosis (MS). Once the motif is detected, the autoimmune disease can be treated or its progress monitored. The autoimmune disease can be treated by administering a peptide comprising the LGRAGLTY motif.
The invention discloses an EGFR (epidermal growth factor receptor) inhibitor for targeted therapy of cancers, and a preparation method and application thereof. The structural formula of the EGFR inhibitor is disclosed as Formula I, wherein R is H, OH, NR&#39;, C1-C3 alkyl, C1-C3 alkenyl, aryl or heterocycle, and R&#39; is C1-C3 alkyl. The EGFR inhibitor can be used for preventing and/or treating cancers, such as human skin squamous carcinoma or lung cancer. Compared with the existing inhibitors (such as AZD9291, afatinib and the like), the EGFR inhibitor disclosed by the invention has novel chemical structure. The EGFR inhibitor can selectively inhibit cell lines of EGFR double mutants (EGFRT790M/L858R), and has lower inhibition activities for EGFR wild type cells. Therefore, the EGFR inhibitor disclosed by the invention can be used for treating the patient with lung cancer with EGFRT790M/L858R mutants, and has lower side effect (caused by the inhibition of the wild type EGFR, such as afatinib).
PURPOSE: To obtain a compression molded preparation by using a preparation additive readily obtainable in the market, having reduced damage of coating film. CONSTITUTION: This compression molded preparation is obtained by compression molding medicine-containing coated particles in the presence of a finely granular film protecting agent. The film protecting agent is fine particles of a substance showing &gt;=50μm average particle diameter and &gt;=4 initial elution rate. A water-soluble saccharide (e.g. glucose), a cellulose derivative (e.g. a carboxyalkyl cellulose), a polysaccharide (e.g. maize starch), a synthetic polymer compound (e.g. polyethylene glycol), a silicon compound (e.g. silicic acid), an alkali metal salt, an alkaline earth metal salt (e.g. calcium carbonate), etc., may be cited as the film protecting agent.  The medicine- containing coated particles are obtained by providing a core substance containing one or more medicines with a coating film for the purpose of sustained release, flavor, improvement in stability, surface modification, etc., and are in sizes of about 30-1,000μm. The medicine-containing coated particles are mixed with the film protecting agent in the ratio of (19:1) to (1:99). The compression molded preparation has higher preparation hardness than that molded by using a protecting agent having a lager particle diameter under the same pressure.
The invention provides compositions and methods for treating neoplastic disease, such as cancer, with an oncolytic virus, such as VSV. A carrier cell is used to target a diseased tissue, and to cloak the oncolytic virus from surveillance by the subject&#39;s immune system during a targeting interval. Following delivery of the virus to the target tissue, the lysis of the carrier cell, and of the target cell, by the oncolytic virus, promotes an adaptive tumouricidal immune response. A wide variety of disparate carrier cells may be used, in conjunction with a promiscuous oncolytic virus having broad tropism, in an approach which facilitates successive treatments in which a new carrier will not be susceptible to an adaptive immune response mounted against previously used carriers. The promiscuity of the virus also facilitates lysis of carrier cells and target cells that are allogenic or xenogenic. The lytic phase of the carrier cell infection is staged so that the carrier is administered in an eclipse phase, and lysis follows the conclusion of the therapeutic targeting interval.